Ep190: Neil Kumar on Building a Rare Disease Drug Company
The Long Run with Luke Timmerman
00:00
Why ATTR cardiomyopathy attracted BridgeBio
Neil outlines the genetic basis of ATTR, rescue mutations, and the rationale for pursuing a potent stabilizer.
Play episode from 34:34
Transcript
